Collectively, our clinical, in vitro and invivo evidence indicated that DOT1L is a marker of aggressive phenotypein human breast cancer that is associated with a worse clinical outcome inER-negative breast cancer and advanced tumour progression related with EMT,invasion and metastasis. This evidence concerns the gene DOT1L and neoplasm.